Decibel Therapeutics is developing regenerative and gene therapy strategies to restore hearing and balance. Using their proprietary platform that integrates single-cell genomics and bioinformatics, Decibel is developing precision gene therapy technologies. These will be used to selectively replace genes for the treatment of congenital, monogenic hearing loss. They are also working to restore hair cell functionality for the treatment of acquired hearing and balance disorders. Ultimately, Decibel Therapeutics is creating a world of connection for people with hearing and balance disorders. 

<p>Decibel Therapeutics is developing regenerative and gene therapy strategies to restore hearing and balance. Using their proprietary platform that integrates single-cell genomics and bioinformatics, Decibel is developing precision gene therapy technologies. These will be used to selectively replace genes for the treatment of congenital, monogenic hearing loss. They are also working to restore hair cell functionality for the treatment of acquired hearing and balance disorders.</p>
<p>Ultimately, Decibel Therapeutics is creating a world of connection for people with hearing and balance disorders. </p>


Decibel Therapeutics

Founded: 2015
Location: Boston, MA
Employee range: 50 - 200
Clinical stage: Clin1b
Therapy area: Cisplatin induced hearing loss
Drug types: OTO, GEN
Lead product: DB-020
Funding: $127M IPO Feb 2021; $82M D Oct 2020; $55M C Jun 2018; Gv investment Jul 2017; $52M A Oct 2015

Drug notes:

About:

Jobs: